276 related articles for article (PubMed ID: 17696203)
21. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
23. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
24. Risk-adapted induction and consolidation therapy in adults with de novo AML aged Heil G; Krauter J; Raghavachar A; Bergmann L; Hoelzer D; Fiedler W; Lübbert M; Noens L; Schlimok G; Arnold R; Kirchner H; Ganser A
Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
26. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
27. Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.
Godwin J
J Natl Cancer Inst Monogr; 1995; (19):31-5. PubMed ID: 7577202
[TBL] [Abstract][Full Text] [Related]
28. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
Tallman MS; Pérez WS; Lazarus HM; Gale RP; Maziarz RT; Rowe JM; Marks DI; Cahn JY; Bashey A; Bishop MR; Christiansen N; Frankel SR; García JJ; Ilhan O; Laughlin MJ; Liesveld J; Linker C; Litzow MR; Luger S; McCarthy PL; Milone GA; Pavlovsky S; Phillips GL; Russell JA; Saez RA; Schiller G; Sierra J; Weiner RS; Zander AR; Zhang MJ; Keating A; Weisdorf DJ; Horowitz MM
Biol Blood Marrow Transplant; 2006 Feb; 12(2):204-16. PubMed ID: 16443518
[TBL] [Abstract][Full Text] [Related]
29. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
[TBL] [Abstract][Full Text] [Related]
30. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
31. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
32. Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
van Geel BM; Huijgens PC; Ossenkoppele GJ; Wijermans PW; Langenhuijsen MM
Neth J Med; 1989 Oct; 35(3-4):128-36. PubMed ID: 2601790
[TBL] [Abstract][Full Text] [Related]
33. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
[TBL] [Abstract][Full Text] [Related]
34. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M
Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786
[TBL] [Abstract][Full Text] [Related]
35. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
Saikia TK; Bakshi A; Bhagwat R; Tawde S; Nair R; Nair CN; Parikh PM
Natl Med J India; 2005; 18(1):12-5. PubMed ID: 15835484
[TBL] [Abstract][Full Text] [Related]
36. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
37. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
Adès L; Chevret S; Raffoux E; de Botton S; Guerci A; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Maloisel F; Deconinck E; Ferrant A; Thomas X; Fegueux N; Chomienne C; Dombret H; Degos L; Fenaux P;
J Clin Oncol; 2006 Dec; 24(36):5703-10. PubMed ID: 17116939
[TBL] [Abstract][Full Text] [Related]
38. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Holowiecki J; Grosicki S; Giebel S; Robak T; Kyrcz-Krzemien S; Kuliczkowski K; Skotnicki AB; Hellmann A; Sulek K; Dmoszynska A; Kloczko J; Jedrzejczak WW; Zdziarska B; Warzocha K; Zawilska K; Komarnicki M; Kielbinski M; Piatkowska-Jakubas B; Wierzbowska A; Wach M; Haus O
J Clin Oncol; 2012 Jul; 30(20):2441-8. PubMed ID: 22508825
[TBL] [Abstract][Full Text] [Related]
39. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
Latagliata R; Breccia M; Fazi P; Iacobelli S; Martinelli G; Di Raimondo F; Sborgia M; Fabbiano F; Pirrotta MT; Zaccaria A; Amadori S; Caramatti C; Falzetti F; Candoni A; Mattei D; Morselli M; Alimena G; Vignetti M; Baccarani M; Mandelli F
Br J Haematol; 2008 Dec; 143(5):681-9. PubMed ID: 18950458
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Bolaños-Meade J; Guo C; Gojo I; Karp JE
Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
